Post-earnings recap
Reported
Wed, Aug 12, 2026
EPS actual
$0.74
EPS est.
$0.70
EPS surprise
+5.26%
1-day move
-10.52%
Liquidia Corporation reported a positive earnings surprise with EPS exceeding expectations, but the stock fell by 10.5% following the report. This decline may reflect investor concerns despite strong sales growth and profitability. The company is on track for significant revenue growth, aiming for over $1 billion by 2027, but the market reaction suggests caution among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.74 | N/A | +5.26% |
| Net Income | $74.7 million | N/A | N/A |
| YUTREPIA Net Product Sales | $170.4 million | N/A | N/A |
| Market Share | 30% | N/A | N/A |
Management expressed confidence in the company's growth trajectory, highlighting strong patient uptake and ongoing investments in the pipeline. They noted the significant increase in YUTREPIA sales and the company's market share in the inhaled treprostinil market.
Management is confident in surpassing $1 billion in net revenue by 2027.
Liquidia Corporation is a pharmaceutical company focused on developing innovative treatments for patients with serious diseases. Operating in the health care sector, Liquidia's work is particularly relevant as the demand for advanced medical therapies continues to grow.
Last quarter
In Q1-2026, Liquidia reported an EPS of $0.52, significantly exceeding expectations of $0.34, leading to a 25.6% increase in stock price the following day. The company continues to show strong performance despite the lack of revenue figures.
EPS beat streak
4Q
EPS beat rate
63%
Avg EPS surprise
+30.33%
Avg 1-day reaction
+3.09%
Overall, expectations are mixed as Liquidia has shown strong EPS surprises in recent quarters, but there is uncertainty regarding revenue figures. Investors are keen to see if this trend continues.
Bull case
If Liquidia can maintain or exceed its recent EPS performance, it could signal strong operational efficiency and market demand for its products, potentially driving the stock higher.
Bear case
Conversely, if the company fails to deliver on revenue or shows signs of slowing growth, it could raise concerns about its long-term viability and lead to a decline in stock price.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
The EPS figure will be crucial in determining whether Liquidia can continue its trend of exceeding expectations and maintaining investor confidence.
Q2
What are the revenue figures for Q2-2026?
Revenue is a critical indicator of the company's growth and market demand for its products, and any surprises could significantly impact stock performance.
—
Est. EPS
$0.20
Est. Rev
$609M
Impl. Move
±12.7%
Why consensus could be wrong
The market may be underestimating Liquidia's ability to sustain its recent EPS growth due to strong demand for its products, which could lead to a positive surprise this quarter.
Supporting evidence
Liquidia has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.
The options market is pricing in a significant move, suggesting that traders expect volatility, which could indicate underlying strength.
The low put/call ratio indicates bullish sentiment among traders, contrasting with the cautious outlook from some analysts.
Key risk
If the EPS comes in above $0.55, it could challenge the current cautious sentiment and lead to a reevaluation of the company's growth potential.
Pre-commit to what would confirm each case.
This quarter's performance hinges on the balance between maintaining strong EPS growth and demonstrating solid revenue figures.
Bull confirmed if
An EPS of $0.55 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $0.40 would confirm the bear case, raising concerns about the company's profitability.
What the market is pricing for the move.
Implied Move
±29.39%
Historical Avg
±7.7%
The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±29.4% while LQDA has averaged ±7.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
78.5%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$6.4M
235,477 sh
1 insider
Net
$6.4M
Net selling
Most Active Insiders· 1 open-market trade
Smart-money positioning from the most recent 13F filings.
Institutional
81.95%
of float
Insider
9.24%
of float
Holders
435
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
10,788,586 sh · $287.8M
12.05%
96.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Liquidia beats expectations, history suggests a potential stock increase of around 6.54%, confirming strong operational strength.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further clarity from management commentary.
Miss
A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 2.44%.
The lines on the call that would change the story.
$6.4M
Net selling
Recent Transactions
Oct 5, 2026 · @ $27.13
235,477 sh
$6.4M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Farallon Capital Management LLC
8,365,038 sh · $223.2M
9.35%
-3.4%
Caligan Partners, LP
8,118,892 sh · $216.6M
9.07%
Flat
Findell Capital Management LLC
3,502,112 sh · $93.4M
3.91%
Flat
Vanguard Capital Management LLC
3,139,183 sh · $83.8M
3.51%
7.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.